SUMMARY Twenty-three patients with sustained, recurrent, symptomatic ventricular tachycardia were treated with oral amiodarone. Initial doses were 600-2000 mg/day and maintenance doses were 200-1200 mg/day. Amiodarone was highly effective in 20 patients (87%), seven of whom had a follow-up of 30 months or longer, including two who were followed for 5 years. Three patients died within the first 45 days, three died suddenly after a follow-up of 33.5 months, and four had a nonarrhythmic death after a follow-up of 25 months. Fifteen patients (65%) had no recurrence during a follow-up of 21.5 months, while five (22%) had isolated recurrences during a follow-up of 32.2 months. The average maintenance dose was 713 mg/day in the 15 patients who did not have recurrences and 375 mg/day in the five patients who had recurrences (p < 0.001). Both short-and long-term tolerance were excellent and there was not a single case in which treatment had to be discontinued. The main disadvantage of amiodarone was that it took an average of 9.5 days to reach antiarrhythmic efficacy. The main advantages were prolonged duration of action (recurrences occurred only 15-60 days after the drug was discontinued or the dose lowered, virtual absence of contraindications, doses as high as 2000 mg/day were safe and patient compliance was excellent.
AMIODARONE is a relatively new antiarrhythmic agent1'4 that has been used successfully in the longterm treatment and prophylaxis of a wide variety of supraventricular and ventricular arrhythmias.4-8 We present our experience using this drug for the longterm management of sustained, recurrent, symptomatic ventricular tachycardia (SRS-VT).
Material and Methods

Patients
Records from 23 consecutive patients admitted to the coronary care unit with the diagnosis of SRS-VT were analyzed. VT was considered sustained when it lasted no less than 30 seconds and nearly always between 10 minutes and several hours (excluding triplets or short salvos), recurrent when two or more episodes were recorded electrocardiographically and symptomatic when the arrhythmia provoked syncope (nine patients), presyncope (16 patients), Stokes- Adams attacks (nine patients), anginal pain (six patients), sudden severe dyspnea or congestive heart failure (14 patients), or cardiogenic shock (two patients). We excluded all cases in which VT was related to reversible phenomena such as hypokalemia, acidbase imbalance, acute sepsis, digitalis or any other form of drug toxicity, as well as patients in whom VT was triggered by a pacing catheter or occurred during or after surgery.
The main clinical and electrocardiographic findings are summarized in table 1. The clinical diagnosis was ischemic heart disease in 14 and cardiomyopathy in nine. In five patients, cardiomyopathy was caused by Chagas' disease. Of the 14 patients with ischemic heart disease, 12 had a documented myocardial infarction, which was 15 days or older in nine and acute in three. In nine of these 12 patients a ventricular aneurysm was documented (during cardiac catheterization in eight). Except for case 18, in whom only two episodes were recorded, all patients had from several to countless attacks. Eight of the 23 had documented episodes of recurrent ventricular fibrillation (VF) and three others had ventricular flutter. The VT was predominantly unifocal and showed a right bundle branch block pattern in the patients with ischemic heart disease, and nearly always multifocal with greater variations in rate in the patients with Chagasic myocarditis. The 45 days (absolute nonresponders), and three after a follow-up of 33.5 months; five (21.7%) had a nonarrhythmic death, four after a follow-up of 25.5 months and one during the acute phase (eighth day).
Side Effects
In no patient did treatment have to be discontinued. Two patients showed late, slowly developing, bluish decoloration of the skin." 1' Acute photosensitivity did not occur in any of the patients, all of whom were males with relatively dark skin. This side effect is more frequent in women and in fair-skinned persons in general. All the patients had corneal microdeposits,"' 12 but only in one was it necessary to reduce tenmporarily the dose because of a minor visual problem. None of the patients developed thyroid abnormalities, deterioration of preexistent heart failure or intraventricular block, or nervous, renal, hepatic or hematologic problems. Discussion Amiodarone, administered orally on a simple, empirical basis, initially caused a comnplete and persistent suppression of SRS-VT in 87% of 23 patients during a follow-up of 24.2 months. Seven patients had a follow-up of 30 months or longer, including two who were followed for 5 years. In 15 of the 23 cases (65%), no recurrences occurred during a follow-up of 21.5 months. In five (22%), recurrences did occur during a follow-up of 32.2 months, but these were clearly related to an insufficient dosage or discontinuance of treatment.
Despite this apparently good antiarrhythmic response, mortality was relatively high; only 13 of the 23 patients (56.6%) were alive at the end of this study. However, the 10 patients who died showed three patterns. Two patients died of arrhythmias within the first 45 days without responding to amiodarone treatment, but received relatively small doses. Three other patients died suddenly after a follow-up of 33.5 months; two of these three were receiving an average dose of 450 mg/day and the third had discontinued treatment. These doses were low by standards reached at the end of the study. Five other patients died from nonarrhythmic causes (cardiac in three, noncardiac in two) after a follow-up of 25.5 months. Accordingly, an arrhythmic death occurred in only five of the 23 patients (21.7%), and in three of these after a followup of 33.5 months.
In SRS-VT, the results of antiarrhythmic treatment may vary considerably and depend to a great extent on the underlying disease, as well as on the drug used. Although this makes comparison of different series difficult, we attempted to compare our results with those reported by others'8'-7 (table 3) . Our analysis shows that not all cases of SRS-VT are equally malignant, and that series including patients in whom the heart is apparently normal and myocardial involvement minimal or absent are more likely to have a better long-term prognosis. In our series, the greater degree of malignancy (regarding both short-and longterm prognosis) appeared to be related to three closely interrelated features; refractoriness to lidocaine, need of repeated electrical cardioversion, and low-output cardiac failure. The most adverse anatomic factor was usually a large ventricular aneurysm.
Advantages and Disadvantages of Amiodarone
The greatest disadvantage of oral amiodarone is the extremely long interval required to reach an effective antiarrhythmic action. In patients who have less serious arrhythmias and take lower doses,6 it has been shown that it takes 4-8 days for the drug to control the arrhythmias. In the present study, the time lag averaged 9.5 days, which may result from a greater degree of refractoriness of the SRS-VT, or may also reflect a lesser bioavailability of the drug under conditions that commonly included low-output cardiac failure and hepatic congestion. In fact, the longer latencies, up to [12] [13] [14] [15] [16] *Miscellaneous includes rheumatic valve disease, mitral valve prolapse, cardiomegaly, hypertensive cardiovascular disease, congenital heart disease, and hemochromatosis.
Abbreviations: Apr = aprindine; Br = bretylium tosylate; CAD = coronary artery disease; CM = cardiomyopathy; D digitalis; DPH diphenylhydantoin; Dis disopyramide; L = lidocaine; MI = myocardial infarction; NHD no heart disease; P = propranolol; PA = procainamide; Q = quinidine; T = tocainide; VA = ventricular aneurysm; VP = ventricular pacing.
amiodarone during the 5-year term of this study; 11 received 103.5 g during the impregnation time of 9.5 days; seven patients received 4557 g during a followup of 30 months or longer, including two who received approximately 900 and 708 g, respectively, during a 5-year period. Despite these huge amounts of drug, in no case did treatment have to be discontinued. The drug was administered in the presence of relative contraindications, such as severe intraventricular block,' 7 but this was done, as also reported by others with other drugs,'6 because of serious symptoms. Treatment was also continued even when two patients had bluish discoloration of the skin. Thus, there were practically no contraindications for the administration of amiodarone, at whatever dose, unlike most antiarrhythmic drugs. However, amiodarone may cause cutaneous and thyroid problems,8' 21-23 and patients should be followed carefully during chronic treatment.
Several patients had long and uninterrupted antiarrhythmic protection on maintenance doses of 400 mg/day, but others required much higher doses. In patients with supraventricular arrhythmias, 400 mg and even 300 or 200 mg/day may be a good maintenance dose,5 'f and if the patient has a recurrence, it is not bound to be extremely dangerous. However, this is not the case in patients with SRS-VT, in whom a single recurrence may cause sudden death. Our study suggests that the maintenance dose of amiodarone for patients with SRS-VT or similarly life-threatening arrhythmias should be no less than 700 mg/day, preceded by 1-2 weeks of loading with 1000-2000 mg/ day. In addition, the use of i.v. amiodarone, which became available only recently, is likely to shorten the loading time and improve the initial response, although this is yet to be proved. If after the first 10-15 days the response is not favorable, the patient should be considered for surgical or other treatment.
The chance of combining amiodarone with other antiarrhythmic drugs should also be considered.
